Squamous cell carcinomas of the hypopharynx (HPSCC) and oropharynx (OPSCC) have markedly different patient outcomes. Differences in HPV prevalence between these two patient groups may account for some of this difference, but other molecular markers of prognosis or pathological phenotype have not been established. Copy number gain of oncogenes is a well-established molecular change contributing to HNSCC development. Quantitative PCR was used to explore copy number gains of specific genes (3q-PIK3CA, TP63; 11q13.3-CCND1, ANO1) in tumor DNA recovered from HPSCC (n 5 48) and OPSCC (n 5 52) patients. Associations between copy number gain, patient demographics, HPV/p16INK4a status and pathological stage were examined. HPV/p16 prevalence in HPSCC and OPSCC groups was 2.1% and 46.0%, respectively. HPSCCs had frequent gains of CCND1 (56.3%) and ANO1 (56.3%) but few gains of PIK3CA (6.3%). By contrast, OPSCCs had significantly fewer CCND1 (23.1%) and ANO1 (17.3%) gains, and significantly more PIK3CA (26.9%) gains. A mutually exclusive relationship between HPV/p16 and 11q13.3 gains was observed in OPSCCs, while PIK3CA and TP63 gains were similar across HPV-associated and smoking/alcohol-associated patients. ANO1 gain was significantly linked to tumor pathology in HPSCC, associating with nodal metastasis and smaller and less invasive tumors at presentation (P 5 0.010). Our results provide a convincing link between a specific molecular change and disease phenotype that appears unique to our HPSCC population, supporting a model of 11q13.3 in promoting metastatic disease progression in HNSCC, and suggest a role for ANO1 as a molecular marker of metastatic disease.
INTRODUCTION
Head and neck cancers remain a major cause of cancer-associated morbidity and mortality worldwide. Squamous cell carcinomas (HNSCC, accounting for more than 90% of head and neck cancers) are now recognised as having at least two distinct aetiological origins. Tobacco and alcohol exposure account for 70 to 80% of cases, but a growing subset in younger patients without this typical risk profile and associated with high risk Human Papillomavirus (HPV) infection are increasingly common in some populations Junor et al., 2012) . Crucially, these different patient subsets have distinct clinical outcomeswith HPV-associated disease fairing favourably in treatment response, recurrence, and survival (Ragin and Taioli, 2007; Klussmann et al., 2009; Fakhry et al., 2008; Junor et al., 2012; Salazar et al., 2014) , providing the basis for a risk stratification process based on the molecular detection of HPV in tumors. Guidelines for HPV annotation of head and neck tumors have been developed for the UK by the Royal College of Pathologists (Helliwell and Woolgar, 2013) , although currently only for OPSCC patients where the link between HPV and prognosis is most apparent. To date, HPV and its co-marker p16INK4A are the only biomarkers in widespread clinical use in the management of HNSCC.
Large-scale next generation sequencing (NGS) projects have profiled HNSCC across multiple molecular and cellular levels, and many themes from early cytogenetic work (including broad, binary distinctions between smoking/alcohol and HPV-associated disease) have now been expanded upon. The consistent observation in early work of a mutually exclusive relationship between amplification of the 11q13.3 chromosomal band (found in high frequency across HNSCC, and other cancers) and the presence of HPV in tumors remains one of the most striking differences observed within HNSCCs (Smeets et al., 2006; Ragin et al., 2006; Klussmann et al., 2009; Lechner et al., 2013; Seiwert et al., 2014) . This separation may be attributable to the divergent mechanisms by which chemical carcinogens (via genetic amplification and consequent over-expression of Cyclin D1 gene CCND1 within the 11q13.3 amplicon-often in combination with genetic or functional loss of restriction point Cyclin Kinase Inhibitor p16INK4A) and HPV (via HPV oncoproteins E6 and E7) achieve dysregulation of the cell cycle. In contrast, certain genetic changes have emerged as common to both HPV and smoking/alcohol-associated HNSCC. For example, mutation, amplification and over-expression of elements of the PI3 kinase pathway (in particular the p110 catalytic subunit gene PIK3CA at 3q26.3) have been consistently observed across both aetiological groups (Smeets et al., 2006; Wilting et al., 2009; Lechner et al., 2013; Cancer Genome Atlas Network, 2015; Keck et al., 2015; Seiwert et al., 2014) .
Integrated NGS analysis has also expanded upon binary aetiological classification, with new subclasses now defined by broad common patterns of copy number change, mutation, transcription and cellular features (now including atypical, classical, mesenchymal/inflammatory and basal classes, as described in Cancer Genome Atlas Network (2015), Keck et al. (2015) , and Seiwert et al. (2014) . Some key areas remain underexplored, however, including whether common specific changes underpin a "switch" from locally invasive to nodal or distant metastatic disease, or underpin the markedly differing outcomes of tumors from different anatomical sites. Any such markers have the potential to be exploited as risk stratification tools, or new therapeutic targets.
In this study, we aimed to explore how copy number gain of HNSCC-associated genes might differ between oropharyngeal (OPSCC) and hypopharyngeal (HPSCC) tumors, and how the observed genetic changes might link to clinicopathological features across the two patient groups. Although less common than other head and neck tumors, HPSCCs have some of the worst outcomes of head and neck tumors (Pulte et al., 2010) , and remain relatively under-researched from a molecular perspective. We developed a qPCR assay to determine copy number gain in specific genes from the commonly amplified 3q arm (PIK3CA, TP63) and 11q13.3 amplicon (CCND1, ANO1). We used this assay to explore the frequency of copy number gains in HPSCC and OPSCC tumors, and using linked patient data we examined the relationships between the observed copy number gains and clinicopathologic characteristics of the two patient groups.
MATERIALS AND METHODS

Patients
Patients referred to the Edinburgh Cancer Centre with histologically confirmed HPSCC ( ) or OPSCC (2011 were identified and relevant demographic and clinicopathologic data extracted from electronic and paper records. Current smokers were defined as patients smoking at presentation, ex-smokers as patients who reported stopping smoking prior to presentation. Social drinkers were defined as patients drinking within recommended weekly alcohol limits (males <18 units, females <14 units), current or past heavy drinkers as patients drinking in excess of these limits at, or prior to presentation, respectively.
HPV and p16 Testing, Genomic DNA Extraction
Sections of formalin fixed paraffin embedded (FFPE) tumor blocks (approved for use by the South East of Scotland BioResource-project reference SR-090) were reviewed and selected by a pathologist to confirm histological diagnosis. Immunohistochemistry (IHC) for p16 was carried out on 3lm sections using a monoclonal antibody to p16 (CINtec Histology, mtm Laboratories) on a Leica Bond III automated immunostainer. IHC for p16 was scored independently by two pathologists, with double review of any cases where there was not consensus, and considered positive if there was strong diffuse nuclear and cytoplasmic staining present in >70% of malignant cells (Singhi and Westra, 2010) .
Tumor genomic DNA was extracted from corresponding sections of FFPE tissue blocks, and from FFPE blocks of normal tonsil tissue (as reference human genomic DNA for qPCR and copy number calculation) as described previously (Junor et al., 2012) . Tumor sections comprised approximately 66% tumor tissue in the majority of cases. HPV testing was performed on extracted genomic DNA using the Optiplex HPV Genotyping Assay (Diamex, Heidelberg, Germany), as described previously (Cuschieri et al., 2013) . DNA extracts were further purified and concentrated by ethanol precipitation and resuspension in nuclease-free water, and samples selected for qPCR based on amount of DNA available (>30 ng total DNA) and spectrophotometric quality (260 nm/280 nm absorption >1.8; 260 nm/230 nm absorption >2.0).
Of 87 HPSCC FFPE samples tested for HPV, 48 were found to have sufficient amounts and quality of DNA for qPCR, and were included in the final genetic amplification analysis (HPSCC n 5 48).
Of 60 OPSCC FFPE samples tested for HPV, 52 were found to have sufficient amounts and quality of DNA for qPCR (OPSCC n 5 52).
Reference and Target Site Selection for qPCR
Target sites for examining copy number gain were selected in genes commonly reported as amplified in HNSCC-two genes on the 3q chromosomal arm (PIK3CA, TP63) and two genes in well-characterized 11q13.3 amplicon (CCND1, ANO1). As a reference gene we selected a chromosomal region infrequently reported as amplified or deleted across the literature-2p23-and within this, the EIF2B4 gene, given its putative constitutive role (initiation of protein translation), no reported involvement in malignant disease, and no current reports of copy number variation. Primer pairs were selected using the Primer3 software tool, with specificity confirmed using the BLAST search tool. Reference and target amplicons were generated using PCR with pooled human genomic DNA (Promega) as template (reaction conditions and primers shown in Supporting Information S1). PCR products were cloned into the Promega pGem-T-easy vector (as per manufacturer's instructions). Sanger sequencing was used to confirm plasmid amplicon specificity.
qPCR and Copy Number Determination qPCR was performed using the Maxima SYBR green master mix (Thermo Scientific) and the Stratagene Mx3000p thermos-cycler (Agilent Technologies). Reaction conditions were optimized (Supporting Information S1) and product specificity assessed using melt curve analysis, using commercial human genomic DNA as substrate. As a valid reference sample for copy number determination in tumor DNA, qPCR was performed and reference copy number values derived from a pool of human genomic DNA extracted from 31 FFPE tissue blocks of normal tonsils with qPCR-confirmed normal copy number (using the ddCt method with above mentioned commercial human genomic DNA as reference). These samples were deemed analogous to the FFPE tumor collection with regard to storage conditions, sample age (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) and extraction procedure, providing a more valid calibrator for tumor copy number calculation. qPCR for each target and reference gene was performed in replicate on tumor (sample) and tonsil (reference/calibrator) genomic DNA. Estimated copy number of target genes in tumor samples was evaluated by relative quantitation using the ddCt method (as described previously in Ginzinger et al., 2000 , Huang et al., 2002 and final copy number calls assigned based on an assumed normal copy number of two in the pooled normal tonsil DNA (as confirmed by comparison to commercially available normal human genomic DNA).
Analysis
To explore relationships between copy number gain, risk factors and tumor stage, patients were grouped according to the presence or absence of target site copy numbers greater than or equal to four (to account for possible stromal/normal tissue contamination in FFPE tumor samples, as described previously in Huang et al., 2006) . Patient groups were compared by tumor site (HPSCC vs. OPSCC) and HPV/p16 status (HPV negative/p16 negative vs. HPV positive/p16 negative vs. HPV negative/p16 positive vs. HPV positive/p16 positive). Presence of any high-risk HPV type in a sample was used to classify patients as "HPV positive," and for purposes of univariate analysis, patients were grouped according to their combined HPV and p16 status (HPV positive/p16 positive versus not HPV positive/p16 positive, including HPV positive/p16 negative, HPV negative/p16 positive, and HPV negative/p16 negative-referred to collectively as "HPV/p16 negative" henceforth). Patients were then grouped by presence or absence of copy number gain at target sites within PIK3CA, TP63, CCND1 or ANO1, and association between gains and clinicopathologic features (sex, smoking, drinking, TNM stage, HPV/p16 status) were examined using univariate analysis. Pearson's v 2 (unless otherwise stated) or Fisher's exact test ("f") were used for univariate analysis between patient groups; age differences were examined using Student's t-test; analysis was performed using IBM SPSS v22.
RESULTS
Demographics, Risk Factors, and Pathological Stage Across Anatomical and HPV/p16 Groups
Comparing patients by anatomical site (Table  1) , HPSCC and OPSCC patients differed significantly with regard to sex (P < 0.001; HPSCCs predominantly male, compared with relative gender equivalence amongst OPSCC), smoking (P 5 0.002; HPSCC predominantly current smokers, OPSCC predominantly never or ex-smokers) and heavy drinking (P 5 0.012; almost half HPSCCs having ex-or current history of heavy drinking, and twice as likely to have heavy drinking history than OPSCCs).
The two anatomical groups differed significantly with regard to HPV/p16 status (P < 0.001)-only one HPSCC tumor was confirmed as HPV positive/p16 positive (all other tumors were HPV negative/p16 negative), this single sample was HPV-18 positive. In contrast 23 of 52 (44.2%) OPSCC tumors were confirmed as HPV positive/p16 positive-with HPV-16 being the commonest highrisk type. HPV and p16 status were significantly associated (P < 0.001)-only four tumors were HPV positive/p16 negative and two HPV negative/p16 positive. Comparing the HPV/p16 negative patient groups across the two anatomical sites (i.e. HPV/p16 negative HPSCC vs. HPV/p16 negative OPSCC, Table 3 ) found these patient groups to be more similar with regard to smoking and drinking history-the two groups remained distinct only with regard to sex (P 5 0.001).
Comparing patients (across both anatomical sites) by HPV/p16 status highlighted significant differences in risk factor history between these two aetiological groups (Table 2 ). Only one of 24 (4.2%) HPV/p16 positive patients was a current smoker, compared with 46 of 74 (63.9%) HPV/p16 negative patients (P < 0.001). Similarly only two Values shown are number (% column total). *P value calculated from grouping patients together (never and social vs. ex and current heavy; never and ex-smoker vs. current smoker; HPV/p16 positive vs. HPV/p16 negative as defined in methods). nk, not known; TNM, as defined by UICC TNM Classification (6th edition); T, tumor size; N, lymph node status; P value indicates significance using Pearson's v 2 test; f, Fisher's exact test; t, Student's t-test.
(9.1%) HPV/p16 positive patients were past or current heavy drinkers, compared with 32 (45.7%) HPV/p16 negative patients (P 5 0.002). Pathological stage at presentation also differed between HPV/p16 groups-HPV/p16 positive primary tumors were more likely to be lower T stage (18 of 24 (75.0%) HPV/p16 positive tumors being T1-3 at presentation, compared with 38 of 74 (51.4%) HPV/p16 negative tumors, P 5 0.034), and more likely to be node metastasis positive at presentation (23 of 24 (95.8%) HPV/p16 positive tumors being node positive at presentation, compared with 49 of 74 (66.2%) HPV/p16 negative tumors, P 5 0.004). Combining T and N stage found HPV/ p16 positive patients significantly more likely to present with smaller or less locally invasive primary but with node positive disease (17 of 24 (70.8%) HPV/p16 positive patients T1-3/N positive at presentation, compared with 25 of 74 (33.8%) HPV/ p16 negative patients; P 5 0.001).
Frequency and Pattern of Target Copy Number Gains Across Anatomical and HPV/p16 Groups
The frequency and pattern of copy number gains at target sites within PIK3CA, TP63, CCND1 and ANO1 genes differed significantly across anatomical and HPV/p16 groups (Tables (1-2); Fig. 1 ). Comparing anatomical groups (Table 1 ; Fig. 1i ), copy number gain of PIK3CA was significantly more common in OPSCC patients (14 of 52 (26.9%) OPSCCs having PIK3CA gain, compared with only three of 48 (6.3%) HPSCCs; P 5 0.006). By contrast, copy number gains of CCND1 and ANO1 were significantly more common in HPSCC patients (27 of 48 (56.3%) of HPSCCs having CCND1 gain, 27 of 48 (56.3%) having ANO1 gain, compared with 12 (23.1%) and 9 (17.3%) of 52 OPSCCs respectively; P < 0.001 in both instances). Frequency of TP63 copy number gain was similar across both HPSCC (9 of 48 (18.8%)) and OPSCC (10 of 52 (19.2%)) groups (P 5 0.951).
Grouping patients by HPV/p16 status revealed significant differences in CCND1 and ANO1 copy number gain frequency (Table 3 ; Fig. 1ii ). No HPV/p16 positive tumors were found to have ANO1 gain (compared with 37 of 74 (50.0%) HPV/ p16 negative tumors), while only one of 24 (4.2%) HPV/p16 positive tumor had CCND1 copy number gain (compared with 35 of 74 (47.3%) HPV/p16 negative tumors) (P < 0.001 in both instances). Frequency of copy number gains at PIK3CA and TP63 target sites were not significantly different between HPV/p16 positive and negative groups Values shown are number (% column total). P value indicates significance using Pearson's v 2 test. *P value calculated from grouping patients together (never and social vs. ex and current heavy; never and ex-smoker vs. current smoker; HPV/p16 positive vs. HPV/p16 negative as defined in methods). nk, not known; TNM, as defined by UICC TNM Classification (6th edition); T, tumor size; N, lymph node status; f, Fisher's exact test; t, Student's t-test. 
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<0.001
Values shown are number (% column total). P value indicates significance using Pearson's v 2 test.
*P value calculated from grouping patients together (never and social vs. ex and current heavy; never and ex-smoker vs. current smoker; HPV/p16 positive vs. HPV/p16 negative as defined in methods). nk, not known; TNM, as defined by UICC TNM Classification (6th edition); T, tumor size; N, lymph node status; f, Fisher's exact test; t, Student's t-test. Comparing the HPV/p16 negative subsets of HPSCC and OPSCC (Table 2 ; Fig. 1iii ), PIK3CA copy number gain remained significantly more common in OPSCCs (8 of 27 (29.6%)) than HPSCCs (3 of 47 (6.4%)) (P 5 0.01f). A higher frequency of CCND1 and ANO1 copy number gains in HPSCC tumors was again apparent-10 of 27 (37.0%) HPV/p16 negative OPSCCs had CCND1 gains, and only eight of 27 (29.6%) had ANO1 gains, compared with 27 of 47 (57.4%) HPV/p16 negative HPSCCs with CCND1 or ANO1 gains (P 5 0.091 and P 5 0.021 respectively).
Synchronous copy number gains were observed with ANO1 and CCND1 in both anatomical groups (24 HPSCC tumors and 9 OPSCC tumors harbouring both CCND1 and ANO1 gains together; P < 0.001 in both instances). TP63 gains were more frequent in HPSCCs and OPSCCs with ANO1/CCND1 gains, but these results were not statistically significant. In HPSCC, PIK3CA gain was mutually exclusive to ANO1 gain (P 5 0.077f)-this pattern was not observed in OPSCC.
Association of Target Copy Number Gains with Pathological Stage
Grouping patients by the presence or absence of copy number gains at target sites revealed a distinct pattern of association between ANO1/CCND1 gain and pathological stage in HPSCC patients, but not in OPSCC patients (Tables (4-6); Fig. 2) . In HPSCC patients, copy number gains of ANO1 were significantly associated with smaller or less invasive (T1-3 vs. T4) primary tumors (18 of 25 (72.0%) T1-3 HPSCCs had ANO1 gain, compared with 9 of 23 (39.1%) T4 tumors; P 5 0.022), and with node positive disease at presentation (22 of 33 (66.7%) node positive HPSCCs had ANO1 gain, compared with 5 of 15 (33.3%) node negative tumors; P 5 0.031) (Fig. 2a) . This association was also significant in smaller (T1-3)/node positive HPSCC tumors (15 of 19 (78.9%) T1-3/node positive HPSCCs had ANO1 gain, compared with 12 of 29 (41.4%) of T4 or node negative T1-3 tumors; P 5 0.010). Similar (but nonsignificant) associations between gains of CCND1 and TP63 and smaller, node positive HPSCC tumors were also observed (Table 1) , though the majority of tumors with copy number gains at CCND1 (24 of 27 (88.9%)) and TP63 (7 of 9 (77.8%)) target sites also had ANO1 gains. No significant pattern of association Figure 1 . Frequency of copy number gains at target genes across HNSCC patients grouped by i) anatomical tumor site (HPSCC n 5 48; OPSCC n 5 52), ii) HPV/p16 status (HPV/p16 negative n 5 47; HPV/p16 positive n 5 27), and iii) anatomical tumor site in HPV/p16 negative tumors (HPV/p16 negative HPSCC n 5 47; HPV/p16 negative OPSCC n 5 27).
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between ANO1 copy number gain (or any other target site) and pathological stage was found in OPSCC tumors, regardless of HPV/p16 status (Tables 3 and 2 ; Fig. 2b) . No significant patterns of association between any copy number gain and risk factor history or patient demographic were found in any patient group (by anatomical site or HPV status).
DISCUSSION
The advent of scalable next generation sequencing technologies brings with it the potential to stratify HNSCCs into new subclasses, framed by tumor aetiology (HPV vs. smoking/alcohol) but defined by distinct common patterns spanning multiple levels of molecular and cellular change (Lechner et al., 2013; Walter et al., 2013;  Values shown are number (% row total). P value indicates significance using Pearson's v 2 test. TNM, as defined by UICC TNM Classification (6th edition); T, tumor size, N, lymph node status; f, Fisher's exact test.
Cancer Genome Atlas Network, 2015; Keck et al., 2015; Seiwert et al., 2014) . In the present study, we targeted one aspect of genetic change that can underlie malignant progression-copy number gain-at specific sites in four genes strongly associated with head and neck cancer-PIK3CA, TP63, CCND1 and ANO1. We find distinct frequencies and patterns of copy number gain across different anatomical and HPV/p16 patient subsets, with PIK3CA gains significantly more common in OPSCC, and CCND1 and ANO1 gains significantly more common in HPSCC. Crucially, we find distinct associations between these molecular changes and pathological features amongst different tumor subgroups, suggesting a possible molecular-pathogenic link between copy number gains in the 11q13.3 band (ANO1, CCND1) and early nodal metastasis in HPSCC.
In our study, the finding of a subset of HPSCCs with ANO1/CCND1 copy number gains that present with node positive and smaller, less locally invasive primary tumors provides a convincing link between a specific molecular change and disease phenotype amongst a specific subset of HNSCCs. Of 27 HPSCCs found to have ANO1 copy number gains, 22 (81.5%) were node-positive at presentation. This finding could suggest a direct contributing role for ANO1 and/or CCND1 copy number gain (likely in the form of the welldocumented high level amplification of the 11q13.3 band leading to over-expression of these and/or other amplicon-resident genes) toward an early "switch" from local invasion to nodal metastasis in HPSCC, resulting in the "smaller primary/ node positive" association observed. Our findings in HPSCC are consistent with other models examining links between 11q13.3 amplification and metastatic potential in HNSCC (Muller et al., 1994; Welkoborsky et al., 2000; Miyamoto et al., 2003; Hermsen et al., 2005; Myo et al., 2005; Rothschild et al., 2006; Ayoub et al., 2010; Sugahara et al., 2011; Pattje et al., 2013; van Kempen et al., 2015) .
Several genes within the 11q13.3 amplicon have been proposed as drivers and markers of recurrence and metastasis, including ANO1 and CCND1. Ano1 (a transmembrane calcium-activated chloride channel) has been suggested to contribute to malignant progression by stabilising EGFR at membrane surfaces (thereby promoting mitogenic stimulus to the cell) (Britschgi et al., 2013; Bill et al., 2015) , but may also directly engage with MAP kinase pathways to promote growth and survival (Duvvuri et al., 2012; Sui et al., 2014) . Although it is often reported in association with metastasis and recurrence in translational studies, other studies have reported effects on proliferation and local invasion (Ruiz et al., 2012; Shiwarski et al., 2014; Jia et al., 2015) , suggesting the tumorigenic functions of Ano1 may be more complex than a "grow to go" switch. Cortactin (CTTN gene) has also been suggested as a potential metastatic driver from the 11q13.3 band, mediating an epithelial-to-mesenchymal switch through interactions with cytoskeletal components (Patel et al., 1996; van Rossum et al., 2005; Rothschild et al., 2006; Luo et al., 2006; Gibcus et al., 2008; Yamada et al., 2010) . Regardless of mechanism, our results suggest that ANO1 copy number gain could act as a strong predictive marker for HPSCC tumors with a high risk of nodal metastasis. Crucial to this supposition would be further studies examining Values shown are number (% row total). P value indicates significance using Pearson's v 2 test. TNM, as defined by UICC TNM Classification (6th edition); T, tumor size, N, lymph node status; f, Fisher's exact test.
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local versus nodal (or distant metastatic) recurrence across the ANO1 gain positive patients, or re-staging in those ANO1 gain positive patients with node negative disease at presentation. Interestingly, our results do not support a similar role for ANO1/CCND1 copy number gain in nodal metastasis in the HPV/p16 negative OPSCC subgroup. It is plausible that the relevant pathways may be affected downstream of the 11q13.3 genes themselves, or by different means (epigenetic change, mutation) in OPSCC. However, this finding could also indicate that the requirements for lymphatic invasion and cell spread differ between the mucosa of the oropharynx and hypopharynx, thus altering the selection pressures between the two tumor types and resulting in different molecular signatures observed in our study.
A mutually exclusive association between 11q13.3 amplification, smoking history and HPV/ p16 has been widely reported across many populations (Smeets et al., 2006; Ragin et al., 2006; Klussmann et al., 2009; Lechner et al., 2013; Seiwert et al., 2014) . Our findings are consistent with this model, observing again an inverse relationship between HPV/p16 status and the presence of CCND1 and ANO1 copy number gains. The pathogenic basis for this genetic distinction likely stems from the selection pressure to overcome the restriction point of G1-to-S cell cycle control in cancer cells. Smoking/alcohol-associated HNSCCs are frequently characterised by amplification and over-expression of Cyclin D1, often complimented by loss of the G1 restriction point Cyclin Kinase Inhibitor p16INK4A, which itself binds and inactivates the Cyclin D1/CDK4 complex. HPVassociated tumors predominantly preserve p16INK4A, and (as observed here) typically preserve normal CCND1 copy number. This reflects the actions of viral oncogene E7 in HPVassociated tumors, which binds and inactivates pRB (releasing the pro-proliferative E2F transcription activating factor) effectively committing cells to S phase down-stream of Cyclin D1/CDK4/ p16INK4A changes, and bypassing the selection pressure to alter Cyclin D1 or p16INK4A found in smoking/alcohol-associated tumors.
Of course, this does not preclude the coexistence of HPV and 11q13.3 amplification in HNSCC, as observed in one patient sample in our study (nor the presence of HPV and the absence of p16, also observed). In some cases, the presence of HPV (whether as "by-stander" infection or cofactor) may not be the primary driver of tumor progression as it is in those HPV/p16 "dual positive" patients, and pre-existing genetic changes (TP53 mutation, p16INK4A loss, or even 11q13.3 changes) may predominate over the actions of HPV E6 and E7. Such instances are most likely in those HPV-positive patients with a smoking history, as suggested in other studies (Keck et al., 2015) Figure 2. Nodal metastasis and T stage are significantly associated with ANO1 copy number gains in HPV/p16 negative HPSCC, but not in HPV/p16 negative OPSCC tumors. ANO1 copy number gains were significantly more frequent in HPV/p16 negative HPSCC tumors with lymph node metastasis (i, P 5 0.031), smaller or less invasive tumors as determined by T stage (ii, P 5 0.022), and in those tumors presenting as both node-positive and T1-3 at presentation (iii, P 5 0.010). ANO1 copy number gain was not significantly different across pathological stage in HPV/p16 OPSCC tumors. *Statistically significant difference (Pearson's v 2 test).
and supported by our own findings. Although these (and other) relationships are somewhat dependent on definitions and detection of HPV/ p16 status (in our study grouping all patients without a combined HPV-positive result and p16-positive result) and are often only possible in the diminishing groups of patients with both HPV and smoking histories, the use of both p16 IHC and direct HPV detection adds validity to these observations, and of the distinct aetiological groups existing within our population. The well-established inverse relationship between HPV and 11q13.3 amplification raises another intriguing question relating to molecularpathological relationships in HNSCC. In our study population, HPV disease almost universally presents with nodal metastasis (some times in the absence of identifiable primary) but these patients are almost universally devoid of 11q13.3 amplification. Given that, by default, 11q13.3 amplification cannot be contributing to nodal metastasis in HPV-associated disease, what factors (host or viral) are driving a "metastatic switch" in HPV/p16 positive patients? In the context of our findings that ANO1/CCND1 gains do not appear to influence a "small primary/node positive" pathological pattern in HPV/p16 negative OPSCCs, it would be interesting to explore whether the specific selection pressures or molecular changes underpinning nodal metastasis are convergent across the HPV/p16 positive and negative OPSCC groups (thereby presenting common biomarkers or future therapeutic targets for metastatic disease across both patient groups), or whether yet more distinct molecular changes underpin this critical disease change in the two patient groups.
From a certain perspective, HPV can be considered a "protective" factor over host genome integrity-by virtue of the "supra-genomic" mechanisms of action of E6 and E7 in enabling unfettered cell proliferation, HPV can essentially supersede two critical selection pressures in tumor cells (knock out of p53; over-ride of G1-to-S restriction point). In so doing, HPV-associated tumors are more likely to maintain functional p53 (and p16INK4a), providing at least the potential for a degree of genomic integrity, which may well underlie the better patient outcomes observed in HPV-associated disease. However, as demonstrated in our study, the presence of HPV alone is not sufficient for malignant progression, with TP63 and PIK3CA copy number gains detectable at equivalent rates in HPV and smoking/alcoholassociated OPSCCs. In addition to exploring the factors associated with nodal metastasis in HPVassociated tumors (as discussed above), it would be of great interest to assess whether E6 and/or E7 expression at a protein level (and other factors linked to this like viral genome integration) correlate to patterns of copy number gain or other mutations, or indeed to patient outcomes.
PIK3CA (encoding the catalytic p110 subunit of PI3 kinase complex) is a well-established oncogene-mutated, amplified, and over-expressed across many common cancers, p110alpha can drive proliferation and survival in tumor cells via activation of central mediator AKT and other downstream elements of the pathway. NGS projects have consistently found PIK3CA gene changes spanning both HPV-associated and smoking/alcohol-associated HNSCC groups (with many reporting increased prevalence of PIK3CA change in HPV-associated disease) (Nichols et al., 2013; Cancer Genome Atlas Network, 2015; Keck et al., 2015; Seiwert et al., 2014) , suggesting a possible common evolutionary requirement for maintaining proliferation or de-differentiation across a majority of HNSCCs. Interestingly, while we did observe PIK3CA gains across both the HPV/p16-positive and HPV/p16-negative OPSCCs at rates consistent with the literature, PIK3CA copy number gain was a rare event in our HPSCC population. This could suggest HPSCCs evolve with different proproliferative signalling mutations, or that the involvement of the PI3 kinase pathway in HPSCCs occurs via mechanisms other than copy number gain or amplification. The lack of association between PIK3CA (or TP63) and pathological stage in our study, combined with the relatively equal distribution across HPV-associated and smoking/alcohol-associated disease add weight to the supposition that these genes have a fundamental role in maintaining proliferation (rather than, for example, driving metastasis) in the subset of tumors harbouring these changes.
Technical differences could potentially contribute to the differences observed in PIK3CA copy number gain frequency between our study and previous work. However this seems unlikely owing to a number of observations and measures. First, in an effort to counter any effect of variability of tumor-to-stroma in our samples, and to reduce any effect of different sample age on results, we selected samples for final analysis based on spectrophotometric quality and quantity of nucleic acid, and performed our analysis based on presence or absence of "large" detectable copy number gains (i.e. more than four copies of a target marker, calculated using the ddCt method). Second, our observation of the well-recognized inverse relationship between HPV/p16 and 11q13.3 copy number gains, together with the strong statistical correlation of CCND1 and ANO1 gains together in the majority of gain-positive samples provides further re-assurance that our PCR assay results reflect plausible copy number changes in the extracted tumor DNA.
The basis for the reported poor outcomes of HPSCC patients is likely to be multifactorial. Outcomes may relate to (i) the anatomical position of this tumor subset, (ii) the often cited extensive comorbidity, and (iii) the lower burden of HPV associated disease (Ernoux-Neufcoeur et al., 2011; Joo et al., 2013; Wendt et al., 2014; Castellsagu e et al., 2016) in this patient group. In addition to demonstrating the low prevalence of HPV in this patient subset, our results show that the molecular signatures of our HPSCC patients are significantly different to those of our OPSCC patients at specific genes. Whether these differences (or other molecular differences not explored in our study) underlie prognosis in our patients remains unclear. Evidence for a prognostic effect of 11q13.3 amplification in HNSCC is inconsistent (Muller et al., 1997; Rodrigo et al., 2000; Namazie et al., 2002; Ashman et al., 2003; Wreesmann et al., 2004; Hermsen et al., 2005; Klussmann et al., 2009; Xavier et al., 2012; Ruiz et al., 2012) , but recent meta-analysis identified ANO1 (along with FADD) as the strongest potential host prognostic biomarkers across HNSCC (Reddy et al., 2016) .
Our study focussed exclusively on the detection of copy number gains of specific genes in the 11q13.3 and 3q sites, however, several other genetic changes have been proposed to occur synchronously with these changes in HNSCC (as reviewed in Gollin, 2014) . Co-amplification between 11q13.3 and 11q22 has recently been confirmed in NGS data (Cancer Genome Atlas Network, 2015), proposed to stem from a selective pressure for amplification and over-expression of both FADD (11q13.3) and BIRC2 (11q22) in HNSCC, with likely antiapoptotic effect. In other studies, 11q13.3 amplification has been associated with deletions of regions distal to 11q14 (Bockm€ uhl et al., 2002; Parikh et al., 2007) , and deletions of 3p regions, each likely to involve loss of tumor suppressor genes which may contribute to disease progression and clinical outcome. Such associations remain under-reported in HPSCC tumors, and future studies in our sample population would benefit from more comprehensive analysis of the effects of combined gain/loss patterns. Given the high frequency of ANO1/CCND1 copy number gain in HPSCC, it would also be interesting to explore whether tumors from this anatomical site fall predominantly within the basal molecular subtype (where 11q13.3 amplification is observed most frequently in other HNSCCs, as described in Cancer Genome Atlas Network, 2015) , and whether this could influence treatment choice in future.
Larger scale studies with sample sizes great enough to control for pathological stage, comorbidity, and treatment modality would be of great value in any future exploration of the apparent molecular-pathogenic differences between our HPV/p16 negative HPSCC and OPSCC patient groups. Given the strong link with nodal metastasis, future studies of tumor recurrence and outcomes in HPSCC in relation to Ano1 and Cyclin D1 amplification and over-expression (and other genes in the 11q13.3 region) are also merited. This could form the basis for a (non-HPV) risk stratification process-with a combination of markers (potentially including ANO1) used to identify those patients with high risk of metastatic disease, thereby altering their management to include systemic therapy, surgical nodal clearance, or more intensive follow-up or re-staging.
